Between 20–25% of all breast cancers are diagnosed in patients younger than 50 years of age, most
of whom are still premenopausal. Currently, tamoxifen is considered the standard of care for adjuvant treatment
in these cases. However, in postmenopausal women, aromatase inhibitors (AIs) are a better choice.
Given the superiority of AIs over tamoxifen in postmenopausal women, multiple investigators explored the
potential role of AIs in premenopausal patients receiving ovarian suppression. Until very recently, available
data derived from the ABCSG-12 clinical trial argued against the combination of AIs and ovarian suppression.
This idea, however, may have changed with the release of the combined analysis of two clinical trials:
SOFT and TEXT which evaluated the use of ovarian suppression in combination therapy. Clinicians will soon
reconsider the possibility of using this strategy for premenopausal patients. Given the availability of this new
data this review will analyze the consequences derived from this study, contextualize this new information
within the vast available literature of anti-hormonal therapy, and discuss potential arguments in favor of and
against the use of this approach.